Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry G M Heijerman

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Journal of Personalized Medicine|June 2, 2021
CFTR Modulators: Does One Dose Fit All?Renske van der Meer, Erik B Wilms, Harry G M Heijerman
Current Opinion in Pulmonary Medicine|September 11, 2019
Prevention of drug-related complications in cystic fibrosisRenske van der Meer, Daan J Touw, Harry G M Heijerman
Current Opinion in Pulmonary Medicine|October 10, 2017
The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendationsFrancis M Hollander, Nicole M de Roos, Harry G M Heijerman
Journal of Personalized Medicine|August 27, 2021
Management of Individual Patient Expectations When Starting with Highly Effective CFTR ModulatorsBente L Aalbers, Inez Bronsveld, Regina W Hofland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 19, 2021
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controlsRenske van der Meer, Erik B Wilms, Richart Sturm, et al.
Acta Oto-Laryngologica|July 9, 2008
Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patientsRenske J Scheenstra, Evert Rijntjes, Dénes L J Tavy, et al.
Acta Oto-Laryngologica|May 30, 2009
No hearing loss after repeated courses of tobramycin in cystic fibrosis patientsRenske J Scheenstra, Harry G M Heijerman, Charlotte L Zuur, et al.
Pediatric Pulmonology|June 12, 2012
Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effectsErik B Wilms, Daniel J Touw, Harry G M Heijerman, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 31, 2019
Aligning patients' needs and research priorities towards a comprehensive CF research programJacquelien J Noordhoek, Vincent A M Gulmans, Harry G M Heijerman, et al.
Clinics (Sao Paulo, Brazil)|August 19, 2023
The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohortLisa M Oppelaar, Bart Luijk, Harry G M Heijerman, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Journal of Personalized Medicine|June 2, 2021
CFTR Modulators: Does One Dose Fit All?Renske van der Meer, Erik B Wilms, Harry G M Heijerman
Current Opinion in Pulmonary Medicine|September 11, 2019
Prevention of drug-related complications in cystic fibrosisRenske van der Meer, Daan J Touw, Harry G M Heijerman
Current Opinion in Pulmonary Medicine|October 10, 2017
The optimal approach to nutrition and cystic fibrosis: latest evidence and recommendationsFrancis M Hollander, Nicole M de Roos, Harry G M Heijerman
Journal of Personalized Medicine|August 27, 2021
Management of Individual Patient Expectations When Starting with Highly Effective CFTR ModulatorsBente L Aalbers, Inez Bronsveld, Regina W Hofland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 19, 2021
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controlsRenske van der Meer, Erik B Wilms, Richart Sturm, et al.
Acta Oto-Laryngologica|July 9, 2008
Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patientsRenske J Scheenstra, Evert Rijntjes, Dénes L J Tavy, et al.
Acta Oto-Laryngologica|May 30, 2009
No hearing loss after repeated courses of tobramycin in cystic fibrosis patientsRenske J Scheenstra, Harry G M Heijerman, Charlotte L Zuur, et al.
Pediatric Pulmonology|June 12, 2012
Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effectsErik B Wilms, Daniel J Touw, Harry G M Heijerman, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 31, 2019
Aligning patients' needs and research priorities towards a comprehensive CF research programJacquelien J Noordhoek, Vincent A M Gulmans, Harry G M Heijerman, et al.
Clinics (Sao Paulo, Brazil)|August 19, 2023
The prevalence of vascular and metabolic complications after lung transplant in people with cystic fibrosis in a Dutch cohortLisa M Oppelaar, Bart Luijk, Harry G M Heijerman, et al.
Pageof 5